CEO Executive AssistantPricing and actuarial work sit at the intersection of technical complexity, regulatory obligation, and competitive strategy. For insurance CEOs, this creates a persistent tension: the function is too important to ignore, yet too specialized for the CEO to own operationally. The result, in many organizations, is a CEO who oscillates between over-involvement in technical pricing decisions and under-involvement in the strategic oversight that actually belongs to them.
The solution is a clear delegation framework: a defined set of decisions the CEO must own, a well-empowered Chief Actuary, and governance structures that keep the CEO informed without making the CEO a bottleneck in the pricing cycle.
Why Actuarial Delegation Is Harder Than It Looks
Actuarial and pricing work involves technical language that can make non-actuaries feel uncertain about which decisions require their input. CEOs may defer to the Chief Actuary on matters they should actually own, or conversely, get pulled into technical discussions where they add little value.
There is also a regulatory dimension. Rate filings, reserve certifications, and actuarial opinions carry legal and regulatory weight. This creates a perception that these matters are too sensitive to delegate, when in reality, the regulatory sensitivity is exactly why a qualified Chief Actuary should own them.
The CEO’s role is to set the strategic context within which actuarial and pricing decisions are made, own the decisions with board-level implications, and hold the Chief Actuary accountable for technical execution. It is not to review actuarial models or participate in pricing committee meetings on a routine basis.
What the Insurance CEO Must Own
Reserve adequacy strategy. Loss reserves represent the company’s largest liability and are subject to board, auditor, and regulatory scrutiny. The CEO is accountable for ensuring that the company’s reserve philosophy is sound, that reserving practices align with the board’s risk appetite, and that reserve changes with material financial impact are understood at the executive level. This does not mean the CEO determines the actuarial estimate, but it does mean the CEO owns the strategic posture: conservative, carried at best estimate, or otherwise.
Major pricing strategy shifts. When the company decides to move from a pure loss cost approach to a more sophisticated segmented pricing model, or to pursue or exit a market segment based on pricing adequacy, those are CEO-level strategic decisions. They involve competitive positioning, capital allocation implications, and distribution consequences that require the CEO’s judgment.
Rate filing decisions with regulatory implications. Some rate filings are routine technical submissions. Others carry material regulatory risk, competitive consequences, or public visibility. When a rate filing could trigger regulatory pushback in a key state, attract media attention, or require regulatory testimony, the CEO should be briefed and may need to be involved in the strategy around that filing, even if the technical work is entirely owned by the Chief Actuary.
Enterprise risk appetite in pricing. The CEO, working with the board and Chief Risk Officer, sets the company’s risk appetite. The Chief Actuary translates that appetite into pricing standards and model parameters. The CEO does not set loss ratio targets by line, but the CEO does own the strategic context that drives those targets.
What the Chief Actuary Should Own
The Chief Actuary is the right owner for the technical and operational layers of actuarial and pricing work. This includes:
- Selection and validation of actuarial models and methodologies
- Rate adequacy analysis by line, segment, and geography
- Actuarial opinions and certifications
- Reserve analysis, including IBNR estimates and development factors
- Pricing model development and ongoing refinement
- Actuarial support for product development and underwriting guidelines
- Rate filing preparation and regulatory actuary relationships
- Catastrophe modeling oversight and reinsurance pricing inputs
The CEO’s relationship with the Chief Actuary should be one of strategic direction and accountability review, not technical management. The CEO should understand the key findings and strategic implications of actuarial work without needing to understand the underlying methodology.
Delegating Pricing Model Development
Pricing model development is a technical function that should rest entirely with the actuarial and data science teams under the Chief Actuary’s direction. The CEO’s involvement in this area is appropriate only at two points: when the company is making a strategic investment in new pricing capabilities, such as implementing a machine learning rating model or launching a telematics program, and when model outputs suggest a strategic pricing shift that requires CEO decision.
For more on how insurance product and pricing strategy connects to operational execution, see insurance product ops.
A practical delegation structure for pricing model work:
CEO: Approves major investments in pricing technology. Reviews aggregate pricing adequacy indicators quarterly. Approves strategic market entries or exits informed by pricing analysis.
Chief Actuary: Owns model selection, validation, and deployment. Reviews pricing adequacy by segment monthly. Escalates to CEO when analysis reveals a strategic issue requiring executive decision.
Actuarial and pricing teams: Execute model development, rate analysis, and pricing committee support. Operate within parameters set by the Chief Actuary.
Empowering Actuarial Teams on Rate Adequacy Analysis
Rate adequacy analysis is one of the most operationally intensive activities in an insurance company. Actuarial teams review loss development, adjust for trend, apply credibility weighting, and produce indications by segment, class, and geography. This work should run on a defined cadence with clear outputs, and it should run without CEO involvement.
The Chief Actuary presents rate adequacy findings to a pricing committee or executive team on a regular schedule, typically quarterly. The output of that presentation is a set of pricing actions: proposed rate changes by state and line that the Chief Actuary recommends based on technical analysis. The CEO’s role at that meeting is to ask about strategic implications, not to evaluate the actuarial methodology.
Building this cadence requires a few structural elements. First, a pricing governance committee with clear authority levels. Rate changes below a defined threshold should be approved by the pricing committee without CEO involvement. Rate changes above the threshold, or changes in states where regulatory dynamics warrant executive awareness, should involve the CEO.
Second, a rate adequacy dashboard that gives the CEO a clear, non-technical view of the company’s pricing position by key segment. This dashboard should answer the question: are we adequately priced in our major markets, and where are the emerging concerns?
Third, a defined escalation path. When the actuarial analysis reveals a situation requiring rapid pricing action or when external developments, such as catastrophic loss activity or competitor pricing moves, require a strategic response, the Chief Actuary knows how to escalate quickly to the CEO.
Managing Pricing Governance Without CEO in Every Rate Change
The goal of actuarial and pricing delegation is a governance system that processes the vast majority of rate changes without CEO involvement, while keeping the CEO appropriately informed and positioned to make the decisions that genuinely require executive authority.
A tiered approval structure works well in most insurance organizations:
Tier 1 (Actuarial team approval): Routine rate changes below a defined premium impact threshold, typically administrative corrections, minor schedule modifications, or changes within a previously approved range.
Tier 2 (Pricing committee approval): Rate changes within defined parameters, including state filings that are consistent with actuarial indication and do not carry elevated regulatory risk.
Tier 3 (CEO or executive team approval): Rate changes above a material financial impact threshold, filings in states with contentious regulatory environments, pricing strategy changes affecting major distribution relationships, or actions departing significantly from actuarial indication for competitive reasons.
This structure allows hundreds of pricing actions per year to move through the organization at the speed of the market, while reserving CEO attention for the situations where executive judgment is genuinely needed.
For additional context on how insurance delegation connects across functions, see insurance distribution delegation.
Common Delegation Failures in Actuarial and Pricing
CEO as pricing committee chair. When the CEO chairs the pricing committee and attends every pricing review, the committee’s authority is effectively transferred to the CEO. Pricing decisions that should be made at the committee level get deferred to the CEO’s judgment. The result is slower pricing actions and a Chief Actuary who is not fully empowered. The CEO should attend pricing governance meetings selectively, not routinely.
Confusing regulatory importance with CEO involvement. Because rate filings are regulatory documents, some CEOs feel they should review or approve individual filings. In most cases, this is the Chief Actuary’s responsibility, with appropriate legal review. The CEO should understand the strategic implications of the company’s regulatory posture, not review individual filing documents.
Under-investing in actuarial leadership. Delegation only works when the leader being empowered has the capability to execute. If the Chief Actuary does not have the technical depth, communication skills, or organizational authority to run the function independently, the CEO will be pulled back in. Investing in a strong Chief Actuary is a prerequisite for effective delegation.
Skipping reserve governance. Some CEOs delegate technical reserve analysis but fail to establish appropriate governance around reserve adequacy decisions. This creates financial reporting risk. The CEO should maintain engagement with reserve decisions at the strategic level through regular dialogue with the Chief Actuary, CFO, and external auditors.
Building an Actuarial Reporting Structure That Keeps the CEO Informed
The CEO should receive a small number of high-quality actuarial updates that convey what they need to know without requiring deep technical engagement. A practical reporting structure:
Monthly: One-page pricing adequacy summary showing combined ratio performance versus plan and key pricing actions taken or pending.
Quarterly: Chief Actuary presentation to executive team covering reserve development, rate adequacy by segment, competitive pricing environment, and key emerging risks.
Annually: Full actuarial review of pricing strategy, reserve position, and actuarial assumptions presented to the board’s audit or risk committee.
This cadence keeps the CEO informed, creates accountability for the Chief Actuary, and ensures the board has the information it needs to provide appropriate oversight of the company’s financial position.
Conclusion
Delegating actuarial and pricing functions effectively requires insurance CEOs to be clear about where strategic ownership ends and technical management begins. The CEO owns reserve strategy, major pricing direction, and regulatory decisions with board-level implications. The Chief Actuary owns technical execution, model development, rate adequacy analysis, and the governance of routine pricing decisions.
When this structure is in place, the actuarial organization runs faster, the Chief Actuary grows into a genuinely strategic partner, and the CEO has the bandwidth to focus on the decisions that only they can make. Pricing and actuarial work remains close to the CEO’s strategic agenda without consuming the CEO’s operational attention.
Related Reading
For further context, explore How Insurance CEOs Delegate Distribution and Agent Management and How Automotive CEOs Delegate Fixed Operations Management.